The DOI matches its Crossref record.
Associations of meningioma molecular subgroup and tumor recurrence
Open accessAbstract
Background: We and others have identified mutually exclusive molecular subgroups of meningiomas; however, the implications of this classification for clinical prognostication remain unclear. Integrated genomic and epigenomic analyses implicate unique oncogenic processes associated with each subgroup, suggesting the potential for divergent clinical courses. The aim of this study was to understand the associated clinical outcomes of each subgroup, as this could optimize treatment for patients. Methods: We analyzed outcome data for 469 meningiomas of known molecular subgroup, including extent of resection, postoperative radiation, surveillance imaging, and time to recurrence, when applicable. Statistical relationships between outcome variables and subgroup were assessed. Features previously associated with recurrence were further investigated after stratification by subgroup. We used Kaplan–Meier analyses to compare progression-free survival, and identified factors significantly associated with recurrence using Cox proportional hazards modeling. Results: Meningioma molecular subgroups exhibited divergent clinical courses at 2 years of follow-up, with several aggressive subgroups (NF2, PI3K, HH, tumor necrosis factor receptor–associated factor 7 [TRAF7]) recurring at an average rate of 22 times higher than others (KLF4, POLR2A, SMARCB1). PI3K-activated tumors recurred earlier than other subgroups but had intermediate long-term outcome. Among low-grade tumors, HH and TRAF7 meningiomas exhibited elevated recurrence compared with other subgroups. Recurrence of NF2 tumors was associated with male sex, high grade, and elevated Ki-67. Multivariate analysis identified molecular subgroup as an independent predictor of recurrence, along with grade and previous recurrence. Conclusion: We describe distinct clinical outcomes and recurrence rates associated with meningioma molecular subgroups. Our findings emphasize the importance of genomic characterization to guide postoperative management decisions for meningiomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EANO guideline on the diagnosis and management of meningiomas
Goldbrunner, R., Stavrinou, P., Jenkinson, M. D., Sahm, F., Mawrin, C., Weber, D. C., Preusser, M., Minniti, G., Lund-Johansen, M., Lefranc, F., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab150 · Cited by 742
Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities
Choudhury, A., Magill, S. T., Eaton, C. D., Prager, B. C., Chen, W. C., Cady, M. A., Seo, K., Lucas, C.-H. G., Casey-Clyde, T. J., Vasudevan, H. N., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01061-8 · Cited by 293
Zuo, Y., Yang, S., & Zhao, W. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1830956 · Cited by 2
Metadata
- Authors
- Youngblood, M. W., Miyagishima, D. F., Jin, L., Gupte, T., Li, C., Duran, D., Montejo, J. D., Zhao, A., Sheth, A., Tyrtova, E., Özduman, K., Iacoangeli, F., Peyre, M., Boetto, J., Pease, M., Avşar, T., Huttner, A., Bilguvar, K., Kilic, T., Pamir, M. N., Amankulor, N., Kalamarides, M., Erson-Omay, E. Z., Günel, M., & Moliterno, J.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-10-17
- Volume
- 23
- Issue
- 5
- Pages
- 783-794
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W3093325233
- Cited by
- 166
- References
- 0
- FWCI
- 13.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Associations of meningioma molecular subgroup and tumor recurrence. https://app.cochat.ai/papers/10.1093/neuonc/noaa226
- The paper
- Youngblood, M. W., Miyagishima, D. F., Jin, L., Gupte, T., Li, C., Duran, D., Montejo, J. D., Zhao, A., Sheth, A., Tyrtova, E., Özduman, K., Iacoangeli, F., Peyre, M., Boetto, J., Pease, M., Avşar, T., Huttner, A., Bilguvar, K., Kilic, T., . . . Moliterno, J. (2021). Associations of meningioma molecular subgroup and tumor recurrence. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaa226
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.